Clinical Trial Update: Open-Label Extension Study of GSK1605786A [Phase 3]

View source ↗

Summary

Open-label extension study results for GSK1605786A in Crohn's disease, a Phase 3 trial that has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• GSK1605786A

Snippet

Sponsor: GlaxoSmithKline | Conditions: Crohn's Disease | Phase 3 | Status: TERMINATED | Results posted: 2017-09-14